Lyra Therapeutics GAAP EPS of -$5.51, revenue of $0.18M

* Lyra Therapeutics press release [https://seekingalpha.com/pr/20198552-lyra-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:LYRA [https://seekingalpha.com/symbol/LYRA]): Q2 GAAP EPS of -$5.51.
* Revenue of $0.18M.
*  

MORE ON LYRA THERAPEUTICS

* Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst [https://seekingalpha.com/article/4795252-lyra-therapeutics-regulatory-pathway-for-non-polyp-patients-a-catalyst]
* Lyra Therapeutics to raise up to $15M via registered direct offering and concurrent private placement, stock falls 22% [https://seekingalpha.com/news/4463246-lyra-therapeutics-to-raise-up-to-15m-via-registered-direct-offering-and-concurrent-private-placement-stock-falls-22]
* Microcap Lyra Therapeutics surges 376% on phase 3 rhinosinusitis data [https://seekingalpha.com/news/4454542-microcap-lyra-therapeutics-surges-376-percent-phase-3-rhinosinusitis-data]
* Seeking Alpha’s Quant Rating on Lyra Therapeutics [https://seekingalpha.com/symbol/LYRA/ratings/quant-ratings]
* Historical earnings data for Lyra Therapeutics [https://seekingalpha.com/symbol/LYRA/earnings]